28032216|t|Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT)
28032216|a|Despite a lower risk of nausea and vomiting in patients receiving radiotherapy to the upper abdomen (UA-RINV) with prophylactic 5-HT3 antagonist therapy, patients can still experience UA-RINV. The aim of this multicenter phase II study was to assess effectiveness, safety, and tolerability of protracted dual NK1-receptor and 5-HT3 antagonist prophylaxis against UA-RINV. Patients receiving fractionated radiotherapy with radiosensitizing chemotherapy received oral ondansetron 8 mg po q12 h and aprepitant 125/80/80 mg on a Monday, Wednesday, Friday schedules throughout radiotherapy. The primary outcome was complete response (CR) defined as no vomiting or rescue therapy during the entire observation period of radiotherapy (OP). Nausea, vomiting, and use of rescue medication were recorded in a modified version of the MASCC antiemesis tool completed twice weekly. Fifty-five patients were enrolled at 5 sites, 52 of whom were evaluable. 57.7% of patients (30/52, 95% CI 43.2-71.3%) achieved CR on study, with 73.1% (38/52, 95% CI 59.0-84.4%) who did not vomit, and 71.2% (37/52, 95% CI 56.9-82.9%) who did not use rescue medication during the OP. Overall, participants vomited or experienced significant nausea (SN) for an average of 6.8% (95% CI 11.4-21.0) and 8.4% (95% CI 4.2-12.7%) of time on study, respectively. Nausea was common with 32 (61.5%) reporting SN at any time during the OP. UA-RINV remains an important morbidity despite the advent of modern radiotherapy. Aprepitant and ondansetron as dosed in this trial was not superior to standard ondansetron monotherapy.
28032216	17	27	aprepitant	T103	UMLS:C1176306
28032216	43	54	ondansetron	T103	UMLS:C0061851
28032216	76	82	nausea	T033	UMLS:C0027497
28032216	87	95	vomiting	T033	UMLS:C0042963
28032216	106	152	fractionated radiotherapy to the upper abdomen	T058	UMLS:C1997554
28032216	154	159	AVERT	T058	UMLS:C1997554
28032216	185	191	nausea	T033	UMLS:C0027497
28032216	196	204	vomiting	T033	UMLS:C0042963
28032216	227	260	radiotherapy to the upper abdomen	T058	UMLS:C1997554
28032216	262	269	UA-RINV	T058	UMLS:C1997554
28032216	276	313	prophylactic 5-HT3 antagonist therapy	T058	UMLS:C2347899
28032216	345	352	UA-RINV	T058	UMLS:C1997554
28032216	370	396	multicenter phase II study	T062	UMLS:C1096776
28032216	438	450	tolerability	T062	UMLS:C3274448
28032216	454	482	protracted dual NK1-receptor	T103	UMLS:C0164209
28032216	487	503	5-HT3 antagonist	T103	UMLS:C0360055
28032216	504	515	prophylaxis	T058	UMLS:C0199176
28032216	524	531	UA-RINV	T058	UMLS:C1997554
28032216	552	577	fractionated radiotherapy	T058	UMLS:C1522449
28032216	583	599	radiosensitizing	T058	UMLS:C0436310
28032216	600	612	chemotherapy	T058	UMLS:C3665472
28032216	622	626	oral	T082	UMLS:C0442027
28032216	627	638	ondansetron	T103	UMLS:C0061851
28032216	657	667	aprepitant	T103	UMLS:C1176306
28032216	733	745	radiotherapy	T058	UMLS:C1522449
28032216	771	788	complete response	T033	UMLS:C4050094
28032216	790	792	CR	T033	UMLS:C4050094
28032216	805	816	no vomiting	T033	UMLS:C0375548
28032216	820	834	rescue therapy	T058	UMLS:C0085405
28032216	853	864	observation	T058	UMLS:C0700325
28032216	875	887	radiotherapy	T058	UMLS:C1522449
28032216	894	900	Nausea	T033	UMLS:C0027497
28032216	902	910	vomiting	T033	UMLS:C0042963
28032216	923	940	rescue medication	T058	UMLS:C0085405
28032216	984	1005	MASCC antiemesis tool	T170	UMLS:C3714902
28032216	1157	1159	CR	T033	UMLS:C4050094
28032216	1163	1168	study	T062	UMLS:C2603343
28032216	1212	1225	did not vomit	T033	UMLS:C0375548
28032216	1280	1297	rescue medication	T058	UMLS:C0085405
28032216	1322	1334	participants	T098	UMLS:C0679646
28032216	1335	1342	vomited	T033	UMLS:C0042963
28032216	1358	1376	significant nausea	T033	UMLS:C0027497
28032216	1378	1380	SN	T033	UMLS:C0027497
28032216	1463	1468	study	T062	UMLS:C2603343
28032216	1484	1490	Nausea	T033	UMLS:C0027497
28032216	1528	1530	SN	T033	UMLS:C0027497
28032216	1558	1565	UA-RINV	T058	UMLS:C1997554
28032216	1626	1638	radiotherapy	T058	UMLS:C1522449
28032216	1640	1650	Aprepitant	T103	UMLS:C1176306
28032216	1655	1666	ondansetron	T103	UMLS:C0061851
28032216	1684	1689	trial	T062	UMLS:C0008976
28032216	1719	1730	ondansetron	T103	UMLS:C0061851
28032216	1731	1742	monotherapy	T058	UMLS:C0087111